Assembly Biosciences, Inc. is a clinical-stage biotechnology company in the United States. The company is headquartered in South San Francisco, California.
| Revenue (TTM) | $74.84M |
| Gross Profit (TTM) | $11.19M |
| EBITDA | $-8.69M |
| Operating Margin | -47.40% |
| Return on Equity | -0.03% |
| Return on Assets | -2.67% |
| Revenue/Share (TTM) | $4.57 |
| Book Value | $15.40 |
| Price-to-Book | 2.41 |
| Price-to-Sales (TTM) | 9.96 |
| EV/Revenue | 5.58 |
| EV/EBITDA | 0.42 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 38.90% |
| Shares Outstanding | $20.36M |
| Float | $9.17M |
| % Insiders | 27.66% |
| % Institutions | 69.35% |
Volatility is currently contracting
The average of price targets set by Wall Street analysts indicates a potential upside of 35.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Assembly Biosciences, Inc. (ASMB) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ASMB's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.
Assembly Biosciences (ASMB) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
LQDT, IA and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 25th, 2026.
IA, ASMB, LQDT, OFG and TGT have been added to the Zacks Rank #1 (Strong Buy) List on August 25th, 2026.
LITE, ONTO and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 21st, 2026.
MCY, ASMB, ONTO, BSET and UNH have been added to the Zacks Rank #1 (Strong Buy) List on August 21st, 2026.
Does Assembly Biosciences (ASMB) have what it takes to be a top stock pick for momentum investors? Let's find out.
The average of price targets set by Wall Street analysts indicates a potential upside of 40.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ASMB and any ticker you trade — then tracks every position and per-strategy win rate.
